WuXi AppTec’s Pharmaceutical Development Services (PDS) division has announced its merger with STA Pharmaceutical Co., Ltd. which is a part of WuXi AppTec group company.

Pre-formulation development, formulation development, as well as Clinical Trial Material (CTM) manufacturing, packaging and labeling of oral solid dosage forms including tablets, capsules, sachets and oral solutions/suspensions comes under the PDS division of company. PDS also established various enabling technology platforms for low soluble drugs including spray dried dispersion, hot melt extrusion, micro or nano suspension and liquid-filled hard gelatin capsules.

After the merger, STA Pharmaceutical will provide fully integrated small molecule Active Pharmaceutical Ingredient (API) and drug product solutions to global clients, resulting in a seamless Chemistry, Manufacturing and Control (CMC) working process. It will also enable STA to advance New Chemical Entities from pre-clinical stage to New Drug Application (NDA) and to market faster and more efficiently for pharma and biotech customers.

Dr. Minzhang Chen, CEO of STA Pharmaceutical, commented: “STA has been growing rapidly over the last few years. It was a natural progression for the company to add drug product to our API platform in which we are globally renowned.”

Dr. Ge Li, Chairman and CEO of WuXi AppTec said, “The merging of the PDS division into STA is an important step for WuXi. Providing API and drug product services under one STA entity further strengthens WuXi’s comprehensive CDMO offering. Ultimately, our platforms advance vital new medicines through the development cycle faster, allowing our global partners to discover and develop better medicines for patients.”